Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9NP59
UPID:
S40A1_HUMAN
Alternative names:
Ferroportin-1; Iron-regulated transporter 1
Alternative UPACC:
Q9NP59; Q6FI62; Q7Z4F8; Q8IVB2; Q9NRL0
Background:
Solute carrier family 40 member 1 (SLC40A1), also known as Ferroportin-1, plays a pivotal role in iron homeostasis. It facilitates the transport of Fe(2+) ions from cells to the extracellular space, ensuring the proper distribution of iron throughout the body. This protein is crucial for dietary iron uptake, iron recycling, and the release of iron stores, with its activity tightly regulated by circulating levels of HAMP/hepcidin in response to serum iron levels.
Therapeutic significance:
SLC40A1's dysfunction is directly linked to Hemochromatosis 4, a disorder characterized by excessive iron accumulation that can lead to organ failure and serious health conditions such as cirrhosis and diabetes. Understanding the role of SLC40A1 could open doors to potential therapeutic strategies for managing iron overload and mitigating the progression of related diseases.